[{"id":"36904a75-f741-450d-9b76-d54c8646a8f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04688853","created_at":"2021-01-19T20:48:13.386Z","updated_at":"2024-07-02T16:36:04.274Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients","source_id_and_acronym":"NCT04688853","lead_sponsor":"Gadeta B.V.","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GDT002"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 05/13/2021","start_date":" 05/13/2021","primary_txt":" Primary completion: 07/30/2023","primary_completion_date":" 07/30/2023","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2022-09-08"}]